207 related articles for article (PubMed ID: 9164211)
61. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
62. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
Litton MJ; Dohlsten M; Rosendahl A; Ohlsson L; Søgaard M; Andersson J; Andersson U
Br J Cancer; 1999 Sep; 81(2):359-66. PubMed ID: 10496366
[TBL] [Abstract][Full Text] [Related]
63. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
[TBL] [Abstract][Full Text] [Related]
64. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
65. Construction and characterization of a novel superantigen fusion protein: bFGF/SEB.
Wang L; Zhang H; Zhang S; Yu M; Yang X
Cancer Invest; 2009 May; 27(4):376-83. PubMed ID: 19160106
[TBL] [Abstract][Full Text] [Related]
66. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly.
Schiller JH; Storer BE; Witt PL; Alberti D; Tombes MB; Arzoomanian R; Proctor RA; McCarthy D; Brown RR; Voss SD
Cancer Res; 1991 Mar; 51(6):1651-8. PubMed ID: 1998956
[TBL] [Abstract][Full Text] [Related]
67. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
Forsberg G; Skartved NJ; Wallén-Ohman M; Nyhlén HC; Behm K; Hedlund G; Nederman T
J Immunother; 2010 Jun; 33(5):492-9. PubMed ID: 20463598
[TBL] [Abstract][Full Text] [Related]
68. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha.
Edwards CK; Zhou T; Zhang J; Baker TJ; De M; Long RE; Borcherding DR; Bowlin TL; Bluethmann H; Mountz JD
J Immunol; 1996 Aug; 157(4):1758-72. PubMed ID: 8759766
[TBL] [Abstract][Full Text] [Related]
69. Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety.
Hao HJ; Jiang YQ; Zheng YL; Ma R; Yu DW
Biochimie; 2005 Aug; 87(8):661-7. PubMed ID: 15927340
[TBL] [Abstract][Full Text] [Related]
70. A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1.
Kuzel T; Rosen ST; Zimmer AM; Silverstein EA; Spies S; Saletan SL; Norvitch ME; Birkhofer M; Shochat D; LoBuglio AF
Cancer Biother; 1993; 8(1):3-16. PubMed ID: 7812346
[TBL] [Abstract][Full Text] [Related]
71. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.
Fishman MN; Thompson JA; Pennock GK; Gonzalez R; Diez LM; Daud AI; Weber JS; Huang BY; Tang S; Rhode PR; Wong HC
Clin Cancer Res; 2011 Dec; 17(24):7765-75. PubMed ID: 21994418
[TBL] [Abstract][Full Text] [Related]
72. Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA.
Rosendahl A; Kristensson K; Carlsson M; Skartved NJ; Riesbeck K; Søgaard M; Dohlsten M
Int J Cancer; 1999 Mar; 81(1):156-63. PubMed ID: 10077167
[TBL] [Abstract][Full Text] [Related]
73. A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.
Shaw DM; Connolly NB; Patel PM; Kilany S; Hedlund G; Nordle O; Forsberg G; Zweit J; Stern PL; Hawkins RE
Br J Cancer; 2007 Feb; 96(4):567-74. PubMed ID: 17285137
[TBL] [Abstract][Full Text] [Related]
74. Monoclonal antibodies and superantigens: a novel therapeutic approach.
Kalland T; Dohlsten M; Lind P; Sundstedt A; Abrahmsén L; Hedlund G; Björk P; Lando PA; Björklund M
Med Oncol Tumor Pharmacother; 1993; 10(1-2):37-47. PubMed ID: 8258993
[TBL] [Abstract][Full Text] [Related]
75. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
Reinhart K; Wiegand-Löhnert C; Grimminger F; Kaul M; Withington S; Treacher D; Eckart J; Willatts S; Bouza C; Krausch D; Stockenhuber F; Eiselstein J; Daum L; Kempeni J
Crit Care Med; 1996 May; 24(5):733-42. PubMed ID: 8706447
[TBL] [Abstract][Full Text] [Related]
76. Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen.
Patterson KG; Dixon Pittaro JL; Bastedo PS; Hess DA; Haeryfar SM; McCormick JK
PLoS One; 2014; 9(4):e95200. PubMed ID: 24736661
[TBL] [Abstract][Full Text] [Related]
77. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.
Parseghian CM; Patnana M; Bhosale P; Hess KR; Shih YT; Kim B; Kopetz S; Overman MJ; Varadhachary GR; Javle M; Naing A; Piha-Paul S; Hong D; Le H; Subbiah V; Pant S
J Immunother; 2018; 41(6):284-291. PubMed ID: 29668571
[TBL] [Abstract][Full Text] [Related]
78. Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors.
Mita MM; Nemunaitis J; Grilley-Olson J; El-Rayes B; Bekaii-Saab T; Harvey RD; Marshall J; Zhang X; Strout V
Target Oncol; 2016 Dec; 11(6):807-814. PubMed ID: 27457707
[TBL] [Abstract][Full Text] [Related]
79. T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.
Lando PA; Dohlsten M; Hedlund G; Akerblom E; Kalland T
Cancer Immunol Immunother; 1993; 36(4):223-8. PubMed ID: 8439985
[TBL] [Abstract][Full Text] [Related]
80. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
Hassan R; Cohen SJ; Phillips M; Pastan I; Sharon E; Kelly RJ; Schweizer C; Weil S; Laheru D
Clin Cancer Res; 2010 Dec; 16(24):6132-8. PubMed ID: 21037025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
